

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药  
LIVZON

麗珠醫藥集團股份有限公司  
**LIVZON PHARMACEUTICAL GROUP INC.\***

(a joint stock company incorporated in the People's Republic of China with limited liability)  
(Stock code: 1513)

**2024 THIRD QUARTERLY REPORT**

This announcement is made by 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.\* (the “**Company**”, together with its subsidiaries collectively, the “**Group**”) pursuant to Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provision under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company and all members of the board of directors (the “**Board**”) warrant that the contents of the information disclosure are true, accurate and complete without containing any false representations, misleading statements or material omissions.

**IMPORTANT NOTICE:**

1. The Board, the supervisory committee and the directors, supervisors and senior management of the Company warrant the truthfulness, accuracy, completeness of the 2024 third quarterly report (the “**Quarterly Report**”) of the Company which does not contain any false representations, misleading statements or material omissions, and accept several and joint legal liabilities for its contents.
2. Mr. Zhu Baoguo (朱保國先生), the person-in-charge of the Company, Ms. Si Yanxia (司燕霞女士), the person-in-charge of accounting work, and Ms. Zhuang Jianying (莊健瑩女士), the person-in-charge of the accounting department (the head of the accounting department), declare that they warrant the truthfulness, accuracy and completeness of the financial information contained in the Quarterly Report.
3. The Quarterly Report was prepared in both Chinese and English. In the event of any discrepancy between the Chinese and the English versions, the Chinese version shall prevail. The financial statements and corresponding information as contained in the Quarterly Report have been prepared in accordance with the China Accounting Standards for Business Enterprises (中國《企業會計準則》). Unless otherwise stated, the currency denominations herein are Renminbi (RMB).
4. Whether the third quarterly report has been audited  
 Yes  No
5. Items with non-standard opinion from the auditor  
 Applicable  Not Applicable

## I. KEY FINANCIAL DATA

### (I) Key Accounting Data and Financial Indicators

Whether the Company has made retrospective adjustments or restatements of accounting data of prior years

Yes  No

	The Reporting Period (July– September 2024)	Period-to-period change	From the beginning of the year to the end of the Reporting Period (January– September 2024)	Period-to-period change
Operating income (RMB)	2,799,249,537.14	-5.59%	9,081,603,788.36	-5.94%
Net profit attributable to the Shareholders of the Company (RMB)	501,763,106.12	7.45%	1,672,733,989.63	4.44%
Net profit attributable to the Shareholders of the Company after deducting the extraordinary gains or losses (RMB)	475,333,392.49	-1.36%	1,630,802,700.28	3.51%
Net cash flow from operating activities (RMB)	–	–	2,307,915,362.28	4.32%
Basic earnings per share (RMB/share)	0.54	8.00%	1.81	5.23%
Diluted earnings per share (RMB/share)	0.54	8.00%	1.81	5.23%
Weighted average return on net assets	3.56%	Increased by 0.13 percentage point	11.63%	Increased by 0.24 percentage point

	End of the Reporting Period	End of last year	Change
Total assets (RMB)	24,909,308,152.30	25,044,827,127.75	-0.54%
Owners' equity attributable to the shareholders of the Company (RMB)	14,158,595,462.73	14,042,495,302.72	0.83%

#### Total share capital of the Company as at the trading day prior to disclosure:

Total share capital of the Company as at the trading day prior to disclosure (shares)	926,904,495
---	-------------

#### Fully diluted earnings per share based on the latest share capital:

Dividends payable to preferred shares (RMB)	–
Interests payable to perpetual bonds (RMB)	–
Fully diluted earnings per share based on the latest share capital (RMB/share)	1.80

## (II) Items and Amounts of Extraordinary Gains or Losses

√ Applicable   □ Not Applicable

Unit: RMB

Items	Amount for the Reporting Period (July – September 2024)	Amount from the beginning of the year to the end of the Reporting Period (January – September 2024)	Explanation
Gains or losses on disposal of non-current assets (including the written-off portion of provisions made for asset impairment)	-303,991.87	-380,432.23	–
Government grants included in profit or loss for the Period (except for government grants closely associated with ordinary operating business of the Company, met national policies and regulations, entitled at fixed level according to certain standards and continuously effected on the Company's profit or loss)	32,137,493.67	75,869,612.54	–
Gains or losses arising from changes in fair value derived from financial assets and financial liabilities held by non-financial enterprises and gains or losses generated on disposal of financial assets and financial liabilities, except for effective hedging activities related to the ordinary operating business of the Company	14,307,386.17	-2,033,718.40	–
Other non-operating income and expenditure apart from the above items	-8,681,746.65	-12,562,709.20	–
Less: Effect of income tax	4,545,891.49	8,971,299.23	–
Effect of minority interests (after tax)	6,483,536.20	9,990,164.13	–
<b>Total</b>	<b>26,429,713.63</b>	<b>41,931,289.35</b>	<b>–</b>

### **Explanation on defining items of extraordinary gains or losses as illustrated in the “Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gains or Losses” as items of recurring gains or losses**

The Company has not defined any items of extraordinary gains or losses as illustrated in the “Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gains or Losses” as items of recurring gains or losses.

### (III) Changes of Key Accounting Data and Financial Indicators and Reasons Thereof

√ Applicable   □ Not Applicable

#### 1. Substantial changes of items in the consolidated balance sheet and reasons thereof

Item	Amount at the end of the Period (RMB)	Amount at the beginning of the year (RMB)	Change	Explanation
Other receivables	55,500,392.38	32,008,338.25	73.39%	Mainly due to the lack of corresponding exercise payments for the exercise portion of share options incentive by employees during the Period.
Other current assets	187,632,168.00	51,549,299.62	263.99%	Mainly due to the new short-term cash management business.
Other non-current assets	658,362,308.31	171,595,133.87	283.67%	Mainly due to the new cash management business.
Financial liabilities held for trading	267,731.76	86,817.12	208.39%	Mainly due to fair value changes in forward foreign exchange contracts.
Contract liabilities	79,012,352.87	137,998,394.09	-42.74%	Mainly because part of the contract payments received in advance in the Period which met the conditions for revenue recognition were transferred to revenue.
Non-current liabilities due within one year	1,631,707,968.32	659,679,477.31	147.35%	Mainly due to the transfer of long-term loans due within one year.
Other current liabilities	11,321,674.26	49,778,126.82	-77.26%	Mainly due to the decrease in expected refunds payable.
Long-term loans	410,756,325.72	1,612,773,278.99	-74.53%	Mainly due to the transfer of long-term loans due within one year in the non-current liabilities due within one year.
Treasury shares	321,173,693.65	—	100.00%	Mainly due to the repurchase of shares for the Period.

## 2. Substantial changes of items in the consolidated income statement from the beginning of the year to the end of the Reporting Period and reasons thereof

Item	Amount for the Period (RMB) (January – September 2024)	Amount for the Previous Period (RMB) (January – September 2023)	Change	Explanation
Operating income	9,081,603,788.36	9,654,792,568.76	-5.94%	See note for details
Finance expenses	-54,930,249.12	-216,475,683.51	74.63%	Mainly due to the decrease in deposit interest income and changes in foreign exchange gains and losses for the Period.
Investment income	25,896,356.13	50,760,662.76	-48.98%	Mainly due to changes in profit or loss from investments in associates.
Gains from changes in fair value	-5,500,365.47	-41,993,723.63	86.90%	Mainly due to fluctuations in the market value of underlying securities investment held.
Credit impairment loss	-326,375.56	-18,668,104.14	98.25%	Mainly due to the decrease in the amount of long aging accounts receivables and the corresponding decrease in expected credit impairment loss.
Asset impairment loss	-60,794,014.54	-108,286,426.69	43.86%	Mainly due to the decrease in provision for inventory impairment during the Period compared to the Previous Period.
Gains from disposal of assets	-370,399.04	-199,730.84	-85.45%	Mainly due to the increase in losses incurred from disposal of fixed assets during the Period.
Non-operating income	4,665,883.32	2,858,014.86	63.26%	Mainly due to the increase in income from disposal of scraps.
Profit and loss attributable to minority interests	273,160,909.93	22,766,303.03	1,099.85%	Mainly due to the increase in the operating profit of non-wholly owned subsidiaries during the Period compared to the Previous Period.
Other comprehensive net income after taxation	-49,894,257.61	-76,284,738.91	34.59%	Mainly due to changes in the fair value of other equity instrument investments and fluctuations in exchange rates which led to changes in translation differences in foreign currency statements.

*Note:* From January to September 2024, the Group recorded an operating income of RMB9,081.60 million, representing a period-to-period decrease of 5.94%. Income from chemical drug preparation products amounted to RMB4,714.47 million, representing a period-to-period decrease of 8.52%, of which, income from gastroenterology products amounted to RMB1,854.14 million, representing a period-to-period decrease of 18.66%; income from gonadotropic hormone products amounted to RMB2,307.69 million, representing a period-to-period increase of 5.46%; income from psychiatry products amounted to RMB443.37 million, representing a period-to-period increase of 3.11%; income from anti-infection and other products amounted to RMB109.27 million, representing a period-to-period decrease of 57.32%. The income from API and intermediate products amounted to RMB2,521.43 million, representing a period-to-period decrease of 2.55%. The income from traditional Chinese medicine preparation products amounted to RMB1,041.15 million, representing a period-to-period decrease of 16.49%. The income from biological products amounted to RMB130.53 million, representing a period-to-period increase of 15.98%. The income from diagnostic reagent and equipment products amounted to RMB566.09 million, representing a period-to-period increase of 21.03%.

**3. Substantial changes of items in the consolidated cash flow statement from the beginning of the year to the end of the Reporting Period and reasons thereof**

<b>Item</b>	<b>Amount for the Period (RMB) (January – September 2024)</b>	<b>Amount for the Previous Period (RMB) (January – September 2023)</b>	<b>Change</b>	<b>Explanation</b>
Effect of changes in foreign exchange rates on cash and cash equivalents	-21,353,488.46	33,034,857.17	164.64%	Mainly due to the changes in foreign exchange rates resulting in the changes in exchange gains and losses from foreign currency funds held.
Net increase in cash and cash equivalents	-253,011,262.94	-76,793,532.42	-229.47%	Mainly due to the increase in repayment of loans.

## II. INFORMATION OF SHAREHOLDERS

### (I) Total Number of Ordinary Shareholders and Preferred Shareholders with Voting Rights Resumed and Shareholdings of the Top 10 Shareholders

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	41,320 (including 41,299 A Shareholders and 21 H Shareholders <sup>Note 1)</sup> )	Total number of preferred shareholders with voting rights resumed as at the end of the Reporting Period (if any)	–
---	--	--	---

#### Shareholdings of the top 10 Shareholders (excluding shares lend through refinancing)

Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of non-tradable shares held	Pledge, charge or lock-up Share status	Number
HKSCC Nominees Limited <sup>Note 2</sup>	Foreign entity	33.11%	306,768,789	–	–	–
Joincare Pharmaceutical Group Industry Co., Ltd. (健康元藥業集團股份有限公司)	Domestic non-state owned entity	23.89%	221,376,789	–	–	–
Hong Kong Securities Clearing Company Limited	Foreign entity	5.51%	51,057,160	–	–	–
Guangzhou Begol Trading Holdings Limited (廣州市保科力貿易公司)	State-owned entity	1.87%	17,306,329	17,306,329	Pledged and locked up	17,306,329
Shenzhen Haibin Pharmaceutical Co., Ltd. (深圳市海濱製藥有限公司)	Domestic non-state owned entity	1.82%	16,830,835	–	–	–
Rui Life Insurance Company Limited – Internal Funds (瑞眾人壽保險有限責任公司–自有資金)	Others	0.84%	7,794,489	–	–	–
Abu Dhabi Investment Authority (阿布達比投資局)	Foreign entity	0.71%	6,555,391	–	–	–
Agricultural Bank of China Limited – CSI 500 Index Open-ended Fund (中國農業銀行股份有限公司–中證500交易型開放式指數證券投資基金)	Others	0.67%	6,210,601	–	–	–
UBS AG	Foreign entity	0.59%	5,437,103	–	–	–
Shanghai Lingren Private Equity Fund Management Partnership (Limited Partnership) – Lingren Excellence Evergreen Phase II Private Equity Securities Investment Fund (上海瓊仁私募基金管理合夥企業(有限合夥)–瓊仁卓越長青二期私募證券投資基金)	Others	0.55%	5,094,949	–	–	–

**Shareholdings of the top 10 Shareholders without selling restrictions**  
(excluding shares held through refinancing, locked shares held by the senior management)

Name of shareholder	Number of publicly traded shares held	Class of shares	Number
HKSCC Nominees Limited <sup>Note 2</sup>	306,768,789	Overseas listed foreign shares	306,768,789
Joincare Pharmaceutical Group Industry Co., Ltd. (健康元藥業集團股份有限公司)	221,376,789	Ordinary shares denominated in RMB	221,376,789
Hong Kong Securities Clearing Company Limited	51,057,160	Ordinary shares denominated in RMB	51,057,160
Shenzhen Haibin Pharmaceutical Co., Ltd. (深圳市海濱製藥有限公司)	16,830,835	Ordinary shares denominated in RMB	16,830,835
Rui Life Insurance Company Limited – Internal Funds (瑞眾人壽保險有限責任公司–自有資金)	7,794,489	Ordinary shares denominated in RMB	7,794,489
Abu Dhabi Investment Authority (阿布達比投資局)	6,555,391	Ordinary shares denominated in RMB	6,555,391
Agricultural Bank of China Limited – CSI 500 Index Open-ended Fund (中國農業銀行股份有限公司– 中證500交易型開放式指數證券投資基金)	6,210,601	Ordinary shares denominated in RMB	6,210,601
UBS AG	5,437,103	Ordinary shares denominated in RMB	5,437,103
Shanghai Lingren Private Equity Fund Management Partnership (Limited Partnership) – Lingren Excellence Evergreen Phase II Private Equity Securities Investment Fund (上海瓚仁私募基金管理合夥企業(有限合夥) –瓚仁卓越長青二期私募證券投資基金)	5,094,949	Ordinary shares denominated in RMB	5,094,949
Monetary Authority of Macao – Internal Funds (澳門金融管理局–自有資金)	4,926,626	Ordinary shares denominated in RMB	4,926,626
Description of connection or acting-in-concert relationship of the above shareholders	(1) On 2 January 2004, Joincare Pharmaceutical Group Industry Co., Ltd. (“Joincare”) and Guangzhou Begol Trading Holdings Limited (“Begol”) entered into a Share Transfer and Custody Agreement and a Share Pledge Agreement, pursuant to which the 6,059,428 shares of the Company held by Begol as original domestic legal shares (the number of shares was increased to 7,877,256 shares after the Company’s implementation of 2014 Equity Distribution, the number of shares was increased to 10,240,432 shares after the Company’s implementation of 2016 Equity Distribution, the number of shares was increased to 13,312,561 shares after the Company’s implementation of 2017 Equity Distribution and the number of shares was increased to 17,306,329 shares after the Company’s implementation of 2018 Equity Distribution) were directly transferred, entrusted and pledged to Joincare; (2) Shenzhen Haibin Pharmaceutical Co., Ltd. was a controlling subsidiary directly and indirectly owned by Joincare as to 100% equity interest; (3) the Company was not aware whether the other shareholders mentioned above are related parties or persons acting-in-concert as defined in the Administrative Measures for the Takeover of Listed Companies (《上市公司收購管理辦法》).		
Description of the top 10 shareholders involved in margin financing and securities lending business (if any)	Not Applicable		



- Notes: 1. The shareholdings of the above top 10 shareholders are listed in accordance with the data in the register of members as at 30 September 2024 provided by Shenzhen Branch of China Securities Depository and Clearing Corporation Limited and Tricor Investor Services Limited in Hong Kong.
2. HKSCC Nominees Limited is a nominee holder of H Shares of the Company, and the Company cannot ascertain whether such H Shares are subject to any pledge or lock-up, and such H Shares held by HKSCC Nominees Limited on behalf of others included 163,364,672 H Shares of the Company held by Topsino Industries Limited (天誠實業有限公司), which was a wholly-owned subsidiary of Joincare, the controlling shareholder of the Company.
3. There is the special repurchase security account among the top 10 shareholders of the Company, and the number of shares held is 7,855,000 shares, which have not been cancelled.

Shareholders holding more than 5%, top 10 Shareholders, and top 10 Shareholders of circulation shares without selling restrictions participating in refinancing business shares lend

Applicable  Not Applicable

Unit: share

Shareholders holding more than 5%, top 10 Shareholders, and top 10 Shareholders of circulation shares without selling restrictions participating in refinancing business shares lend

Name of shareholder (full name)	Number of shares held by ordinary accounts and credit accounts at the Beginning of the Period		Number of outstanding shares lent through refinancing at the Beginning of the Period		Number of shares held by ordinary accounts and credit accounts at the End of the Period		Number of outstanding shares lent through refinancing at the End of the Period	
	Aggregate number	Percentage of total share capital	Aggregate number	Percentage of total share capital	Aggregate number	Percentage of total share capital	Aggregate number	Percentage of total share capital
Agricultural Bank of China Limited – CSI 500 Index Open-ended Fund (中國農業銀行股份有限公 司—中證500交易型開放式指 數證券投資基金)	1,964,635	0.21%	596,800	0.06%	6,210,601	0.67%	–	–

Changes compared to the Previous Period due to lending/returning for refinancing by the top 10 Shareholders and the top 10 Shareholders of circulation shares without selling restrictions

Applicable  Not Applicable

**(II) Total Number of Preferred Shareholders of the Company and Shareholdings of the Top 10 Preferred Shareholders**

Applicable  Not Applicable

### III. OTHER IMPORTANT EVENTS

Applicable    Not Applicable

#### (I) The Progress of Repurchase of Shares

##### 1. *The progress of repurchase of A Shares*

As at 30 September 2024, the Company made a total repurchase of 7,855,000 A Shares of the Company by means of centralized bidding transactions, accounting for 0.85% of the total share capital of the Company. The highest purchase price was RMB36.80 per share, while the lowest purchase price was RMB32.95 per share. The aggregate amount of funds used for the repurchase was RMB276,508,263.84 (excluding the transaction costs). The above mentioned repurchase complied with the Company's existing Share Repurchase Scheme.

##### 2. *The progress of repurchase of H Shares*

As at 30 September 2024, the Company made a total repurchase of 4,763,400 H Shares of the Company (of which 2,778,800 Shares have been cancelled on 28 June 2024), with the uncanceled H Shares accounting for 0.21% of the total share capital of the Company. The highest purchase price was HK\$26.15 per share, while the lowest purchase price was HK\$23.05 per share. The aggregate amount of funds used for the repurchase was HK\$116,981,345.00 (excluding the transaction costs). The above mentioned repurchase complied with the Company's general mandate to repurchase H Shares.

## (II) Share Options Exercised at the Discretion under the Share Options Incentive Scheme

On 18 December 2023, the Company held the ninth meeting of the eleventh session of the Board, at which the Resolution on the Fulfillment of Exercise Conditions for the First Exercise Period under the First Grant of the 2022 Share Option Incentive Scheme of the Company was considered and approved. The exercise conditions for the first exercise period of the First Grant under the 2022 Share Option Incentive Scheme of the Company have been fulfilled, and 1,001 incentive participants who met the exercise conditions were approved to exercise 7,045,000 share options in the first exercise period at the exercise price of RMB31.31 per A share. Upon review by the Shenzhen Stock Exchange and the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited, the relevant share options will be exercisable commencing from 2 January 2024. The abbreviation of the share options that can be exercised is Livzon JLC3, and the code of the share options is 037312. As at 30 September 2024, share options exercised at the discretion of the First Grant under the 2022 Share Option Incentive Scheme are as follows:

Name	Position	Number of share options under the First Grant (0'000)	Number of share options exercisable (0'000)	Number of share options exercised at the discretion (0'000)
Tang Yanggang	Director and President	16.00	6.40	–
Xu Guoxiang	Vice Chairman and Vice President	16.00	6.40	–
Yang Daihong	Vice President	12.00	4.80	–
Du Jun	Vice President	12.00	4.80	–
Si Yanxia	Vice President and Chief Financial Officer	12.00	4.80	–
Huang Yuxuan	Vice President	12.00	4.80	–
Yang Liang	Vice President and Secretary to the Board	12.00	4.80	–
Mid-level management and relevant core personnel of the Company (994 persons)		1,669.25	667.70	544.9514
1,001 persons in total		1,761.25	704.50	544.9514

## IV. QUARTERLY FINANCIAL STATEMENTS

### (I) Financial Statements

#### Consolidated Balance Sheet

Prepared by: Livzon Pharmaceutical Group Inc.

Unit: RMB

Item	Amount at the End of the Period	Amount at the Beginning of the Year
<b>Current assets:</b>		
Monetary funds	10,732,685,456.90	11,325,723,855.76
Financial assets held for trading	76,472,630.38	81,792,081.22
Bills receivable	1,273,854,877.42	1,459,333,093.74
Accounts receivables	2,146,824,180.61	2,115,658,645.12
Receivables financing		
Prepayments	150,998,534.03	139,458,224.63
Other receivables	55,500,392.38	32,008,338.25
Of which: Interest receivable		
Dividends receivable		
Inventories	1,989,425,761.87	2,060,651,179.94
Contract assets		
Held-for-sale assets		
Non-current assets due within one year		
Other current assets	187,632,168.00	51,549,299.62
<b>Total current assets</b>	<b>16,613,394,001.59</b>	<b>17,266,174,718.28</b>
<b>Non-current assets:</b>		
Debt investments		
Other debt investments		
Long-term receivables		
Long-term equity investments	1,076,344,299.46	1,031,259,800.84
Other equity instrument investments	584,273,384.49	638,843,775.68
Other non-current financial assets		
Investment properties	10,136,074.99	10,766,737.57
Fixed assets	4,327,803,862.18	4,294,232,468.83
Construction in progress	269,107,411.95	289,306,707.05
Productive biological assets		
Oil and gas assets		
Right-of-use assets	20,476,619.94	20,908,112.56
Intangible assets	410,429,292.75	426,283,093.35
Development expenditure	305,820,048.21	287,888,786.16
Goodwill	124,911,302.94	124,911,302.94
Long-term deferred expenses	180,196,233.44	180,732,214.07
Deferred income tax assets	328,053,312.05	301,924,276.55
Other non-current assets	658,362,308.31	171,595,133.87
<b>Total non-current assets</b>	<b>8,295,914,150.71</b>	<b>7,778,652,409.47</b>
<b>Total assets</b>	<b>24,909,308,152.30</b>	<b>25,044,827,127.75</b>

Item	Amount at the End of the Period	Amount at the Beginning of the Year
<b>Current liabilities:</b>		
Short-term loans	2,050,000,000.00	1,860,009,625.00
Financial liabilities held for trading	267,731.76	86,817.12
Bills payables	1,047,051,310.97	894,588,217.10
Accounts payables	669,865,293.23	763,825,157.69
Receipts in advance		
Contract liabilities	79,012,352.87	137,998,394.09
Employee benefits payables	281,176,461.06	264,432,630.74
Taxes and surcharge payables	227,157,751.42	299,087,995.28
Other payables	3,015,704,774.73	3,157,651,033.59
Of which: Interest payable		
Dividends payable	10,022,086.38	12,478,280.13
Held-for-sale liabilities		
Non-current liabilities due within one year	1,631,707,968.32	659,679,477.31
Other current liabilities	11,321,674.26	49,778,126.82
<b>Total current liabilities</b>	<b>9,013,265,318.62</b>	<b>8,087,137,474.74</b>
<b>Non-current liabilities:</b>		
Long-term loans	410,756,325.72	1,612,773,278.99
Bonds payables		
Leasing liabilities	8,443,738.21	9,030,622.57
Long-term payables		
Long-term employee benefits payables		
Provisions		
Deferred gains	244,185,740.59	269,370,462.59
Deferred income tax liabilities	206,867,284.94	209,812,292.82
Other non-current liabilities	90,000,000.00	90,000,000.00
<b>Total non-current liabilities</b>	<b>960,253,089.46</b>	<b>2,190,986,656.97</b>
<b>Total liabilities</b>	<b>9,973,518,408.08</b>	<b>10,278,124,131.71</b>
Share capital	926,608,853.00	923,938,139.00
Other equity instruments		
Of which: Preferred shares		
Perpetual bonds		
Capital reserve	1,352,680,195.45	1,322,498,474.23
Less: treasury shares	321,173,693.65	
Other comprehensive income	107,928,218.42	143,071,567.85
Special reserve		
Surplus reserve	744,801,154.15	744,801,154.15
Undistributed profits	11,347,750,735.36	10,908,185,967.49
Total equity attributable to shareholders of the parent company	14,158,595,462.73	14,042,495,302.72
Minority interests	777,194,281.49	724,207,693.32
<b>Total shareholders' (or owners') equity</b>	<b>14,935,789,744.22</b>	<b>14,766,702,996.04</b>
<b>Total liabilities and shareholders' (or owners') equity</b>	<b>24,909,308,152.30</b>	<b>25,044,827,127.75</b>

Chairman of the Board and Legal Representative:  
Zhu Baoguo

Executive Director and President:  
Tang Yanggang

Chief Financial Officer:  
Si Yanxia

Head of Accounting Department:  
Zhuang Jianying

## Consolidated Income Statement from the Beginning of the Year to the End of the Reporting Period

Prepared by: Livzon Pharmaceutical Group Inc.

Unit: RMB

Item	Amount for the Period (January – September 2024)	Amount for the Previous Period (January – September 2023)
<b>I. Operating income</b>	<b>9,081,603,788.36</b>	9,654,792,568.76
Less: Operating costs	<b>3,104,994,916.67</b>	3,482,687,323.90
Tax and surcharge	<b>104,952,254.81</b>	114,898,186.83
Selling expenses	<b>2,456,192,166.74</b>	2,814,431,433.12
Administrative expenses	<b>472,580,469.22</b>	486,955,984.56
R&D expenses	<b>734,493,897.75</b>	985,755,413.94
Finance expenses	<b>-54,930,249.12</b>	-216,475,683.51
Of which: Interest expenses	<b>68,262,462.24</b>	74,677,672.33
Interest income	<b>146,128,180.20</b>	271,989,020.64
Add: Other income	<b>93,195,566.84</b>	119,087,222.15
Investment income (“-” represents losses)	<b>25,896,356.13</b>	50,760,662.76
Of which: Income from investments in associates and joint ventures	<b>18,288,587.10</b>	47,375,552.22
Gains on derecognition of financial assets at amortized cost (“-” represents losses)		
Gains from hedging net exposure (“-” represents losses)		
Gains from changes in fair value (“-” represents losses)	<b>-5,500,365.47</b>	-41,993,723.63
Credit impairment loss (“-” represents losses)	<b>-326,375.56</b>	-18,668,104.14
Asset impairment loss (“-” represents losses)	<b>-60,794,014.54</b>	-108,286,426.69
Gains from disposal of assets (“-” represents losses)	<b>-370,399.04</b>	-199,730.84
<b>II. Operating profit (“-” represents losses)</b>	<b>2,315,421,100.65</b>	1,987,239,809.53
Add: Non-operating income	<b>4,665,883.32</b>	2,858,014.86
Less: Non-operating expenditure	<b>17,228,592.52</b>	19,987,199.49
<b>III. Total profit (“-” represents total losses)</b>	<b>2,302,858,391.45</b>	1,970,110,624.90
Less: Income tax expenses	<b>356,963,491.89</b>	345,789,442.91
<b>IV. Net profit (“-” represents net losses)</b>	<b>1,945,894,899.56</b>	1,624,321,181.99
(I) Classified by continuing operations:		
Of which: Net profit from continuing operations (“-” represents net losses)	<b>1,945,894,899.56</b>	1,624,321,181.99
Net profit from discontinued operations (“-” represents net losses)		
(II) Classified by attribution to ownership:		
Of which: Net profit attributable to shareholders of the parent company (“-” represents net losses)	<b>1,672,733,989.63</b>	1,601,554,878.96
Profit and loss attributable to minority interests (“-” represents net losses)	<b>273,160,909.93</b>	22,766,303.03

Item	Amount for the Period (January – September 2024)	Amount for the Previous Period (January – September 2023)
<b>V. Other comprehensive net income after taxation</b>	<b>-49,894,257.61</b>	-76,284,738.91
Other comprehensive net income after taxation attributable to shareholders of the parent company	<b>-49,606,276.66</b>	-76,943,788.56
(I) Other comprehensive income not to be reclassified into profit or loss	<b>-58,575,448.32</b>	-100,795,388.94
1. Changes in remeasurement of defined benefit plans		
2. Other comprehensive income not to be reclassified into profit or loss under equity method		
3. Changes in fair value of other equity instrument investments	<b>-58,575,448.32</b>	-100,795,388.94
4. Changes in fair value of enterprise's own credit risk		
5. Others		
(II) Other comprehensive income to be reclassified into profit or loss	<b>8,969,171.66</b>	23,851,600.38
1. Other comprehensive income to be reclassified into profit or loss under equity method	<b>-383,527.54</b>	366,793.26
2. Changes in fair value of other debt investments		
3. Financial assets reclassified into other comprehensive income		
4. Credit impairment provision for other debt investments		
5. Reserve for cash flow hedging (effective portion of profit or loss from cash flow hedging)		
6. Translation differences of financial statements denominated in foreign currency	<b>9,352,699.20</b>	23,484,807.12
7. Others		
Other comprehensive net income after taxation attributable to minority interests	<b>-287,980.95</b>	659,049.65
<b>VI. Total comprehensive income</b>	<b>1,896,000,641.95</b>	1,548,036,443.08
Total comprehensive income attributable to shareholders of the parent company	<b>1,623,127,712.97</b>	1,524,611,090.40
Total comprehensive income attributable to minority interests	<b>272,872,928.98</b>	23,425,352.68
<b>VII. Earnings per share</b>		
(I) Basic earnings per share	<b>1.81</b>	1.72
(II) Diluted earnings per share	<b>1.81</b>	1.72

Chairman of the Board and Legal Representative: Executive Director and President: Chief Financial Officer: Head of Accounting Department:

Zhu Baoguo                      Tang Yanggang                      Si Yanxia                      Zhuang Jianying

## Consolidated Cash Flow Statement from the Beginning of the Year to the End of the Reporting Period

Prepared by: Livzon Pharmaceutical Group Inc.

Unit: RMB

Item	Amount for the Period (January – September 2024)	Amount for the Previous Period (January – September 2023)
<b>I. Cash flow from operating activities:</b>		
Cash received from sale of goods and services rendered	9,877,413,424.19	10,195,691,388.01
Refund of taxes and levies	61,319,520.23	82,241,227.89
Cash received relating to other operating activities	278,375,294.28	497,329,281.67
<b>Subtotal of cash inflow from operating activities</b>	<b>10,217,108,238.70</b>	<b>10,775,261,897.57</b>
Cash paid for purchase of goods and services received	2,548,981,042.82	3,125,599,585.75
Cash paid to and on behalf of employees	1,296,813,399.77	1,193,090,639.89
Payments for various taxes and levies	1,133,102,962.42	1,103,449,696.01
Cash paid relating to other operating activities	2,930,295,471.41	3,140,718,620.53
<b>Subtotal of cash outflow from operating activities</b>	<b>7,909,192,876.42</b>	<b>8,562,858,542.18</b>
<b>Net cash flow from operating activities</b>	<b>2,307,915,362.28</b>	<b>2,212,403,355.39</b>
<b>II. Cash flow from investing activities:</b>		
Cash received from disposal of investments	437,976,402.50	374,334,588.68
Cash received on investment income	12,838,374.07	70,124,524.03
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	420,612.67	7,381,053.01
Net cash received from disposal of subsidiaries and other operating units		
Cash received relating to other investing activities		6,000,000.00
<b>Subtotal of cash inflow from investing activities</b>	<b>451,235,389.24</b>	<b>457,840,165.72</b>
Cash payments for acquisition of fixed assets, intangible assets and other long-term assets	405,237,689.81	554,644,502.79
Cash payments for investments	671,914,636.75	407,636,113.68
Net cash paid for acquisition of subsidiaries and other operating units		22,461,951.59
Cash paid relating to other investing activities	1,404,603.34	27,027,492.56
<b>Subtotal of cash outflow from investing activities</b>	<b>1,078,556,929.90</b>	<b>1,011,770,060.62</b>
<b>Net cash flow from investing activities</b>	<b>-627,321,540.66</b>	<b>-553,929,894.90</b>



<b>Item</b>	<b>Amount for the Period (January – September 2024)</b>	<b>Amount for the Previous Period (January – September 2023)</b>
<b>III. Cash flow from financing activities:</b>		
Cash received from investments	<b>161,751,999.95</b>	39,240,000.00
Of which: Cash received by subsidiaries from investments of minority interests		39,240,000.00
Cash received from borrowings	<b>3,004,143,152.42</b>	2,731,170,168.70
Cash received relating to other financing activities	<b>1,062,615.02</b>	
<b>Subtotal of cash inflow from financing activities</b>	<b>3,166,957,767.39</b>	2,770,410,168.70
Cash paid on repayment of debts	<b>3,044,697,628.28</b>	2,330,352,425.04
Cash paid for distribution of dividends, profits or interest	<b>1,640,266,373.96</b>	1,843,923,076.72
Of which: Dividends and profits paid to minority interests by subsidiaries	<b>319,631,193.75</b>	303,850,432.96
Cash paid relating to other financing activities	<b>394,245,361.25</b>	364,436,517.02
<b>Subtotal of cash outflow from financing activities</b>	<b>5,079,209,363.49</b>	4,538,712,018.78
<b>Net cash flow from financing activities</b>	<b>-1,912,251,596.10</b>	-1,768,301,850.08
<b>IV. Effect of changes in foreign exchange rates on cash and cash equivalents</b>	<b>-21,353,488.46</b>	33,034,857.17
<b>V. Net increase in cash and cash equivalents</b>	<b>-253,011,262.94</b>	-76,793,532.42
Add: Balance of cash and cash equivalents at the beginning of the Period	<b>10,976,366,402.44</b>	10,072,642,681.72
<b>VI. Balance of cash and cash equivalents at the end of the Period</b>	<b>10,723,355,139.50</b>	9,995,849,149.30

*Chairman of the Board and Legal Representative:* *Executive Director and President:* *Chief Financial Officer:* *Head of Accounting Department:*  
*Zhu Baoguo* *Tang Yanggang* *Si Yanxia* *Zhuang Jianying*

**(II) Adjustments to the Financial Statements as at the Beginning of the Year Due to the Application of New Accounting Standards for the First Time Since 2024**

Applicable  Not Applicable

**(III) Audit Report**

**Whether the third quarterly report has been audited**

Yes  No

The third quarterly report of the Company has not been audited.

By order of the Board  
**Livzon Pharmaceutical Group Inc.\***  
麗珠醫藥集團股份有限公司  
**Yang Liang**  
Company Secretary

Zhuhai, China  
23 October 2024

*As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman) and Mr. Qiu Qingfeng; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.*

\* For identification purpose only